TKIs (afatinib, lapatinib, neratinib, dacomitinib) targeting Ex20Ins EGFR have been shown to have limited activity in patients with EGFR-Ex20Ins-mutant tumors, with exception of the covalent inhibitor poziotinib, which has been found to demonstrate greater activity in vitro (Yasuda et al., 2013; Ruan and Kannan, 2018; Robichaux et al., 2018) and in patient-derived xenograft models of EGFR Ex20Ins mutant NSCLC and in genetically engineered mouse models of NSCLC (Robichaux et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.